Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AT-587 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AT-587 Dose 1 (Day 1) | EXPERIMENTAL | AT-587 administered orally, dose 1 on Day 1 |
| Placebo -Dose 1 (Day 1) | PLACEBO_COMPARATOR | Matching placebo dose 1 administered orally on Day 1 |
| AT-587 Dose 2 (Day 1 and Day 7) | EXPERIMENTAL | AT-587 administrated orally, dose 2 on Day 1 and Day 7 |
| Placebo-Dose 2 (Day 1 and Day 7) | PLACEBO_COMPARATOR | Matching placebo dose 2 administered orally on Day 1 and Day 7 |
| AT-587 Dose 3 - (Day 1) | EXPERIMENTAL | AT-587 administered orally, dose 3 on Day 1 |
| Placebo - Dose 3 - (Day 1) | PLACEBO_COMPARATOR | Matching placebo dose 3 administered orally on Day 1 |
| AT-587 Dose 4 - (Day 1) | EXPERIMENTAL | AT-587 administered orally, dose 4 on Day 1 |
| Placebo - Dose 4- (Day 1) | PLACEBO_COMPARATOR | Matching placebo dose 4 administered orally on Day 1 |
| AT-587 - Dose 5 (Day 1-7) | EXPERIMENTAL | AT-587 - administered orally, dose 5 (QD) for 7 days |
| Placebo- Dose 5 (QD) (Day 1-7) | PLACEBO_COMPARATOR | Matching placebo dose 5 administered orally once daily (QD) for 7 days |
| AT-587 - Dose 6 split (BID) (Day 1-7) | EXPERIMENTAL | AT-587 administered orally, dose 6 daily split (BID) for 7 days |
| Placebo - Dose 6 (BID) (Day 1-7) | PLACEBO_COMPARATOR | Matching placebo administered orally dose 6 daily split (BID) for 7 days |
| AT-587 - Dose 7 (QD) or split (BID) daily (Day 1-7) | EXPERIMENTAL | AT-587 administered orally, dose 7 (QD) or split (BID) for 7 days |
| Placebo - Dose 7 (QD) or split (BID) (Day 1-7) | PLACEBO_COMPARATOR | Matching placebo administered orally, dose 7 daily (QD) or split (BID) for 7 days |
| Name | Type | Description |
|---|---|---|
| AT-587 | DRUG | Parallel Assignment |
| Placebo | OTHER | Parallel Assignment |
Inclusion Criteria: * Body mass index (BMI) of 18-29 kg/m2 * Must agree to use protocol-specified methods of contraception * Negative pregnancy test * Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: * Pregnant or breastfeeding * Abuse of a...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
AT-587 is an investigational small molecule being developed for the treatment of Hepatitis E. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
AT-587 targets HEV replication, which refers to the process by which the Hepatitis E virus multiplies within host cells. By interfering with this process, the drug aims to inhibit viral replication.
AT-587 is being developed by Atea Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol AVIR.
AT-587 is in Phase 1 clinical development. It is an investigational drug and has not yet received approval from regulatory agencies for the treatment of Hepatitis E.
AT-587 is being studied in a Phase 1 clinical trial with the identifier NCT07728487. This trial is titled 'Study of AT-587 in Healthy Subjects' and is currently recruiting participants in Belgium.
Yes, AT-587 is being tested in a Phase 1 clinical trial that enrolls healthy volunteers. The study, identified as NCT07728487, is a randomized, double-blind, placebo-controlled trial with an estimated enrollment of 62 participants.